IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
Metrics to compare | 287840 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship287840PeersSector | |
|---|---|---|---|---|
P/E Ratio | −63.5x | −16.2x | −0.4x | |
PEG Ratio | −40.00 | −0.43 | 0.00 | |
Price/Book | 27.2x | 4.0x | 2.6x | |
Price / LTM Sales | 292.8x | 23.0x | 3.1x | |
Upside (Analyst Target) | - | 0.0% | 58.6% | |
Fair Value Upside | Unlock | 4.0% | 8.2% | Unlock |